EDUCATION BROCHURE

SAVE 20% WHEN YOU REGISTER BY 2/24

FEATURING OVER 230 HOURS OF EDUCATION, INCLUDING CUTTING-EDGE CLINICAL CONTENT DEVELOPED SPECIFICALLY FOR VISION EXPO

BROUGHT TO YOU BY

Produced by

VEE2022.COM/LEARN
We’re thrilled to introduce new pricing which makes VisionEd more accessible and affordable than ever! Take advantage of unlimited education for one day, or upgrade to unlimited education for the entire CE Program to take advantage of everything VisionEd has to offer.*

ALL EDUCATION REGISTRATIONS INCLUDE THE FOLLOWING:

- ADMISSION TO EXHIBITS ($150 VALUE)
- ADMISSION TO EDUCATION ATTENDEE LOUNGE
- EDUCATION REGISTRATION PROCESSING FEE ($50 VALUE)

EARLY BIRD RATES: APPLY ON OR BEFORE 2/24/22
REGULAR RATES: APPLY AFTER 2/24/22

*Unlimited education package does not include workshops.

**SAVE 20%**
When you register for courses before 2/24/2022!

**DOCTORS**

<table>
<thead>
<tr>
<th><strong>UNLIMITED CONTINUING EDUCATION</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Early Bird: $499</td>
</tr>
<tr>
<td>Regular: $599</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>ONE DAY EDUCATION</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Early Bird: $339</td>
</tr>
<tr>
<td>Regular: $409</td>
</tr>
</tbody>
</table>

**OPTICON / ALLIED HEALTH**

Opticians, contact lens professionals, allied ophthalmic professionals, optical assistants and office managers, frame buyers and lab technicians.

<table>
<thead>
<tr>
<th><strong>OPTICON @ VISION EXPO</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>UNLIMITED CONTINUING EDUCATION</td>
</tr>
<tr>
<td>Early Bird: $249</td>
</tr>
<tr>
<td>Regular: $299</td>
</tr>
</tbody>
</table>

**OTHER PROFESSIONALS**

Professionals working in corporate management, or service providers

<table>
<thead>
<tr>
<th><strong>UNLIMITED CONTINUING EDUCATION</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Early Bird: $449</td>
</tr>
<tr>
<td>Regular: $539</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>ONE DAY EDUCATION</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Early Bird: $319</td>
</tr>
<tr>
<td>Regular: $389</td>
</tr>
</tbody>
</table>

**WORKSHOPS**

$186
2SL1: Scleral Lens Workshop
30C5: OCT Workshop

*Unlimited education package does not include workshops.

**FREE EDUCATION**

- Global Contact Lenses Forum: 10L1, 10L2, 10L3
- March Madness Imaging Program: 10C1, 10C2, 10C3 (10C2 workshop limited to first 50 registrants)
- Vision Series (Optometrists Only)
- Innovation Stage

*Advance Registration is required for free courses.

**Topcon Chronos combines autorefration, keratometry and subjective refraction in a single device that takes up less than 4 feet of space. The fully automated system, which features SightPilot® guided refraction software, enables easy operation, and binocular testing means refractions take less time than traditional methods, allowing you to see more patients and grow your practice.**

**VISIT US AT VEE2022 BOOTH F4533 FOR A DEMO**

©2022 Topcon Healthcare | topconhealthcare.com

**WE WORK HARD TO FIND THE BEST DEALS SO YOU DON’T HAVE TO!**

Book your NYC hotel today to secure our discounted rate at VEE2022.COM/HOTEL
2022 VISION EXPO ADVERTISERS

SUPPORTERS

Mark Dunbar, OD, FAAO, Co-Chairman
CAB Chairman, Michigan College of Optometry at Ferris State University

Ben Gaddie, OD, FAAO, Co-Chairman
CAB Chairman, University of Alabama at Birmingham School of Optometry

Douglas Devries, OD
Pacific University College of Optometry

Michael Kling, OD
Southern College of Optometry

Thomas Quinn, OD
Ohio University College of Medicine

Jack Schaeffer, OD
University of Georgia, Southern College of Optometry

Kirk Smick, OD, FAAO
Former CAB Chairman, Pacific University College of Optometry

Vincent Young, MD
Temple University, Temple University Medical School

EDUCATION ADVISORY BOARD
MEET THE MEMBERS WHO HAVE BEEN ACTIVELY INVOLVED IN THE DEVELOPMENT OF THIS YEAR’S EDUCATION MEETING.

Janet Acara, ABOC, NCLEM
Erie Community College

Tom Barracato, ABOC, NCLEC
Owner, Adolph Optical

Sandra K. Brown, ABOM, NCLEC
VisionWorks

Curt Duff, ABOM, NCLEC
Owner, Tinder-Krauss-Tinder

David F. Meldrum, ABOM, NCLEC
Mount Vernon Eye Care

Tina Palumbo
OAB Co-Chair, Foerster & Hayes LTD, ABO-NCLE Board Public Member

Carri L. Russell, NCLEM
Bausch Health Speciality Vision Products
NCLE Chair

Sandra K. Brown, ABOM, NCLEC
VisionWorks

Curt Duff, ABOM, NCLEC
Owner, Tinder-Krauss-Tinder

David F. Meldrum, ABOM, NCLEC
Mount Vernon Eye Care

OPTICON ADVISORY BOARD
MEET THE MEMBERS WHO HAVE BEEN ACTIVELY INVOLVED IN THE DEVELOPMENT OF THIS YEAR’S EDUCATION MEETING.

Janet Acara, ABOC, NCLEM
Erie Community College

Tom Barracato, ABOC, NCLEC
Owner, Adolph Optical

Sandra K. Brown, ABOM, NCLEC
VisionWorks

Curt Duff, ABOM, NCLEC
Owner, Tinder-Krauss-Tinder

David F. Meldrum, ABOM, NCLEC
Mount Vernon Eye Care

Tina Palumbo
OAB Co-Chair, Foerster & Hayes LTD, ABO-NCLE Board Public Member

Carri L. Russell, NCLEM
Bausch Health Speciality Vision Products
NCLE Chair

Sandra K. Brown, ABOM, NCLEC
VisionWorks

Curt Duff, ABOM, NCLEC
Owner, Tinder-Krauss-Tinder

David F. Meldrum, ABOM, NCLEC
Mount Vernon Eye Care

Tina Palumbo
OAB Co-Chair, Foerster & Hayes LTD, ABO-NCLE Board Public Member

Carri L. Russell, NCLEM
Bausch Health Speciality Vision Products
NCLE Chair

Sandra K. Brown, ABOM, NCLEC
VisionWorks

Curt Duff, ABOM, NCLEC
Owner, Tinder-Krauss-Tinder

David F. Meldrum, ABOM, NCLEC
Mount Vernon Eye Care

Blair Wong, ABOM, NCLEC
OAB Co-Chair, Benjamin Franklin Institute of Technology-Opticianry Department Chair

Official Institutional Sponsor: New England College of Optometry
CLINICAL HIGHLIGHTS

GLAUCOMA
11C1 The Glaucoma Suspect: Clinical Pearls for Optimal Management
13C1 Innovations in Glaucoma Drug Delivery: What the Future Holds
21C1 A Roadmap for Making the Diagnosis in Glaucoma
23C1 Treating the Newly Diagnosed Glaucoma Patient
24C1 New Medications in Glaucoma
25C1 A Roadmap for Identifying and Managing Progression in Glaucoma
26C1 A Roadmap for Medical Management of Glaucoma
30C4 MIGS in Glaucoma
30C5 OCT Workshop
33C1 Glaucoma Grand Rounds
34C1 Surgical Advances in Glaucoma Therapy

ANTIOR SEGMENT
12C2 Biologics in the Optometric Practice: Lowering Inflammation With Amniotic Tissue
12C3 Going Viral: HZO, HSV, EKC
13C2 Are You Ready for Ocular Allergy Armageddon?
21C2 Pain Photophobias and Ocular Pathology: What You Should Know to Help Your Patient
22C2 Updates in Corneal Collagen Crosslinking
24C4 Treatment of Inflammatory Eyelid Disease with Photobiomodulation Therapy
25C2 MGD: New Technologies for Diagnosis and Management
30C7 Neurotrophic Cornea
31C2 Uveitis
33C2 Advances in Ocular Surface Disease: Treating Dry Eye
34C2 Digital Dry Eye
42C2 CSI: Anterior Segment Case Files
42C3 Red Eyes – It’s Just Conjunctivitis or Is It?

BELEPHARITIS
26C2 Anterior Segment Dilemmas
31C3 Demodex Principal, Conspirator, or Bystander in Dry Eye
32C2 The Greatest Anterior Segment Disease and Medical Management of Contact Lens Complications Course Ever
34C4 Don’t Let Your Lids Get You Down

IMAGING TECHNOLOGY
10C1 March Madness: Case Challenges in Optometry - Optimizing Ocular Imaging Workshop
10C2 March Madness: Case Challenges in Optometry – Optimizing Ocular Imaging Round 1
10C3 March Madness: Case Challenges in Optometry – Optimizing Ocular Imaging Semifinals and Finals
22C3 OCTA
23C3 How OCT Forever Changed Retina
30C6 10 Hacks for OCT Interpretation in Glaucoma
31C5 OCT Connect: Maximizing Your OCT

SURGICAL/CO-MANAGEMENT
22C4 Aesthetics in Optometry... a Therapeutic Approach: IPL
23C6 Laser Therapy and Advanced Procedures Optometry
25C4 Rapidly Changing Landscape of Refractive Technology
33C4 20/20 Refractive Update: Advances in Presbyopic and Corneal Procedures
43C1 A New Era in Cataract and Refractive Surgical Management

CONTACT LENS
10L1 Roadmap to Success in Contact Lens Practice
10L2 Lessons Learned from Favorite Contact Lens Cases
10L3 Unconventional Marketing of Your Specialty Lens Practice
22L1 Scleral Lenses 101: Basic Fitting
23L1 Scleral Lens Advanced Fitting
24L1 Scleral Lens Troubleshooting
25L1 Scleral Lens Workshop
26L1 New and Innovative Uses for Contact Lenses
31L1 Tricks of the Trade with Torics
32L1 The Art and Science of +0.50 CL Fitting
33L1 Diagnosis and Treatment of the Irregular Cornea
42L1 Contact Lens Management of Keratoconus

LOW VISION
25C3 Today’s Low Vision Made Easy
26C3 Low Vision Triage: The Gap Between Simple Magnification and Braille

POSTERIOR SEGMENT/RETINA:
21C5 The OD Role in Diabetes
25C5 The Greatest Posterior Segment Disease Course Ever
26C5 21st Century Retina Care

PHARMACOLOGY
11C3 Oral Pharmaceuticals for Anterior Segment Disease
25C6 Therapeutic Approaches to Presbyopia Management: The Dawn of a New Age
33C6 Top 10 Drugs: What’s In Your Cabinet
34C6 Ocular Pain Management

OPTOMETRIC/SURGICAL PROCEDURES
13C1 Innovations in Glaucoma Drug Delivery: What the Future Holds
22C2 Updates in Corneal Collagen Crosslinking
22C4 Aesthetics in Optometry...a Therapeutic Approach: IPL

HANDS ON WORKSHOP
25L1 Scleral Lens Workshop
30C5 OCT Workshop

CLINICAL CONTENT
Custom designed for Vision Expo by the Education Advisory Board, our 2022 program is organized by key content areas including glaucoma, posterior segment/retina, anterior segment/dry eye, surgical/co-management, and systemic disease and diabetes. Here you will discover courses specifically developed to immerse you in the most cutting-edge developments for better patient care. Learn from the most knowledgeable experts in the field of optometry as they unveil leading-edge technology and the latest trends in the diagnosis and treatment of common eye diseases. Nine clinical tracks with over 100 hours of content will keep you at the forefront of the industry.
EDUCATION HIGHLIGHTS

MYOPIA TRACK

3OC6 Unlocking the Mystery of Myopia Management 7 Keys to Success

OWNER’S AND MANAGER’S ESSENTIALS PROGRAM

Reflecting today’s biggest business challenges, this program for owners, managers and key decision makers will focus on the business side, including strategies to grow your business. Critical areas of focus include marketing your practice, growing and transitioning your practice, measuring financial success, building a great staff, competing in a digitally connected world, and building the ultimate optical business.

21B2 How To Become the Best Leader to Make Your Team Smarter
23B4 How I Built This: Building a New Practice from the Ground Up
32C6 Unlocking the Mystery of Myopia Management 7 Keys to Success

SCLERAL LENS TRACK

Scleral lens fitting is one of the fastest growing segments of specialty contact lens practice. Their impact can be profound and life changing, both to the patient and the practice. This tract will provide comprehensive and highly clinical information on how to select a scleral lens design for both basic and advanced cases, how to assess the fit and how to solve problems that may develop. Learn skills that will take your abilities and patient satisfaction to the next level.

Supported by an unrestricted educational grant from: Bausch & Lomb

22L1 Scleral Lenses 101: Basic Fitting
23L1 Scleral Lenses: Advanced Fitting
24L1 Scleral Lenses Troubleshooting
25L1 Scleral Lens Workshop

VISION SERIES

This all-new-for-2022 format invites you to grab a bite to eat or drink and continue learning over lunch. Take a break from the exhibit hall or formal classroom learning as industry leaders address the latest clinical innovations in a relaxed and collaborative learning environment. Then put theory into practice by heading back into the exhibit hall to connect and build on your classroom learning. Vision Series sessions are open to Optometrists only and are limited to one session per day. NOT FOR CREDIT.

Please check our website east.visionexpo.com for the list of Vision Series sessions.

INNOVATION STAGE

Located in The Bridge, the all-new Innovation Stage features free exhibitor-sponsored content for all attendees. Learn about the latest products and services over complimentary snacks and beverages in a casual, soft-seating environment.

Please check our website east.visionexpo.com for the list of Innovation Stage sessions.

F R E E E D U C A T I O N

GLOBAL CONTACT LENS FORUM

This free, informative and highly attended ‘meeting within a meeting’ provides attendees with practical, timely tips in both clinical and business processes that will take your specialty contact lens practice to the next level. A panel of respected, highly successful contact lens practitioners will provide personal insights gleaned from their road map to success. This will be followed by grand round case presentations highlighting key problem-solving strategies in specialty contact lens practice. Finally, learn valuable practice management tips for billing and coding in specialty lens practice.

THE GLOBAL CONTACT LENS FORUM IS DIRECTED BY THOMAS QUINN, OD

SUPPORTED BY AN UNRESTRICTED EDUCATIONAL GRANT FROM: BAUSCH + LOMB, COOPERVISION, JOHNSON & JOHNSON VISION

THURSDAY, MARCH 31

7:00 AM - 8:00 AM
10L1 - Roadmap to Success in Contact Lens Practice
Moderator: Thomas Quinn, OD
Panelists: Milton Hom, OD; Shalu Patel, OD; David Kading, OD

8:00 AM - 9:00 AM
TBA
Speaker: TBA
Presented by: Coopervision

9:15 AM - 11:15 AM
10L2 - Lessons Learned from Favorite Contact Lens Cases
Speakers: Thomas Quinn, OD; Milton Hom, OD; Shalu Patel, OD; David Kading, OD

11:30AM-12:30PM
10L3 - Unconventional Marketing of Your Specialty Lens Practice
Speaker: David Kading, OD

12:15 AM-12:30PM
10L4 - 7 Keys to Success in Contact Lens Practice
Speaker: Thomas Quinn, OD

12:30PM-1:00PM
Promotional Lunch Symposium
TBA
Speaker: TBA
Presented by: Johnson & Johnson Vision
NOT FOR CREDIT

MARCH MADNESS

In the spirit of high stakes competition, panelists will compete against each other by presenting interesting cases highlighting imaging technology. The audience decides who wins each match via attendee interactive polling technology. The competition is fierce and the stakes are high as the loser goes home and the winner advances until the final showdown. Come be a part of this unique program that captures the thrill of victory and the agony of defeat as a champion gets crowned.

SUPPORTED BY AN UNRESTRICTED EDUCATIONAL GRANT FROM: LUNEAU TECHNOLOGY USA (VISIONIX, BRIOT WECO), ICARE USA, AND ZEISS

THURSDAY, MARCH 31

11:30AM-1:30PM
10C1 – March Madness: Case Challenges in Optometry - Optimizing Ocular Imaging Workshop
Speakers: Mark Dunbar, OD, FAAO
LIMITED ATTENDANCE

1:30PM-3:30PM
10C2 – March Madness: Case Challenges in Optometry - Optimizing Ocular Imaging Round 1
Moderator: Mark Dunbar, OD, FAAO
Panelists: Julie Rodman, OD; Mohammad Rafieetary, OD; Steven Ferrucci, OD; Steven Ferrucci, OD; Marc Sutton, OD; Carolyn Majcher, OD; Jay Haynie, OD; Joseph Pizmentelli, OD; Sherrol Reynolds, OD

3:45PM-4:45PM
10C3 – March Madness: Case Challenges in Optometry - Optimizing Ocular Imaging Semifinals and Finals
Moderator: Mark Dunbar, OD, FAAO
Panelists: Julie Rodman, OD; Mohammad Rafieetary, OD; Steven Ferrucci, OD; Marc Sutton, OD; Carolyn Majcher, OD; Jay Haynie, OD; Joseph Pizmentelli, OD; Sherrol Reynolds, OD

Interested in more information or assistance? Contact us directly: west.visionexpo.com

5 HOURS FREE CE | ADVANCED REGISTRATION REQUIRED | ACCREDITATION PENDING - COPE, NCLE, FL BOARDS OF OPTOMETRY + OPTICIANRY, NY STATE OPTICIAN - CONTACT LENS - INTERMEDIATE
**THURSDAY MARCH 31**

### FREE! GLOBAL CONTACT LENS FORUM

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
<th>Accreditations</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM–8:00 AM</td>
<td><strong>10L1 - FREE</strong> Roadmap to Success in Contact Lens Practice</td>
<td>Quinn</td>
<td>C,FL-OD,FL-OP,N-NO,NYS-CL-I</td>
</tr>
<tr>
<td>9:15 AM–10:15 AM</td>
<td><strong>10L2 - FREE</strong> Lessons Learned from Favorite Contact Lens Cases</td>
<td>Quinn, Ham, Pal, Kading</td>
<td>C,FL-OD,FL-OP,N-NO,NYS-CL-I</td>
</tr>
<tr>
<td>11:30 AM–12:30 PM</td>
<td><strong>10L3 - FREE</strong> Unconventional Marketing of Your Specialty Lens Practice</td>
<td>Kading</td>
<td>C,FL-OD,FL-OP,N-NO,NYS-CL-I</td>
</tr>
</tbody>
</table>

### CLINICAL

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
<th>Track Key</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15 AM–1:15 PM</td>
<td><strong>11C1</strong> The Glaucoma Suspect: Clinical Pearls for Optimal Management</td>
<td>Chaglasian</td>
<td>Glaucoma</td>
</tr>
<tr>
<td>12:30 PM–2:30 PM</td>
<td><strong>11C2</strong> Oral Pharmaceuticals for Anterior Segment Disease</td>
<td>Lightbor</td>
<td>Pharmacology</td>
</tr>
<tr>
<td>1:30 PM–3:30 PM</td>
<td><strong>11C3</strong> Biologics in the Optometric Practice: Lowering Inflammation With Amniotic Tissue Dervies</td>
<td>C,FL-OD,T&amp;TA</td>
<td>Optometric/Surgical Procedures</td>
</tr>
<tr>
<td>1:30 PM–3:30 PM</td>
<td><strong>11C4</strong> Modern Day Diabetes Insurance: How to prevent or reverse 2 diseases from 2 different &amp; distinct</td>
<td>C,FL-OD,T&amp;TA</td>
<td>Optometric/Surgical Procedures</td>
</tr>
<tr>
<td>3:45 PM–5:45 PM</td>
<td><strong>12C2</strong> Are You Ready for Ocular Allergy Armageddon?</td>
<td>Hom</td>
<td>Myopia</td>
</tr>
<tr>
<td>5:00 PM–6:00 PM</td>
<td><strong>12C3</strong> Innovations in Glioma Drug Delivery: What the Future Holds</td>
<td>Schweitzer</td>
<td>Non-Track</td>
</tr>
</tbody>
</table>

### OPTICAL TECHNOLOGY

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
<th>Accreditations</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30</td>
<td><strong>11B2</strong> Developing The CEO Within You</td>
<td>Carlson</td>
<td>C,FL-OD</td>
</tr>
<tr>
<td>12:15</td>
<td><strong>11B3</strong> Creating Perceived Value</td>
<td>Hom</td>
<td>A-NO</td>
</tr>
<tr>
<td>1:00</td>
<td><strong>11B4</strong> Applying Retail Strategies in the Optical Dispensary</td>
<td>Martin</td>
<td>C,FL-OD</td>
</tr>
</tbody>
</table>

### BUSINESS SOLUTIONS

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
<th>Track Key</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:45</td>
<td><strong>13C2</strong> Visual Perception: From Photon to Neuron</td>
<td>Hom</td>
<td>Glaucoma</td>
</tr>
<tr>
<td>1:15</td>
<td><strong>13C3</strong> Are You Ready for Ocular Allergy Armageddon?</td>
<td>Hom</td>
<td>Myopia</td>
</tr>
</tbody>
</table>

**PROGRAM SUBJECT TO CHANGE AS OF 01-18-22.**

Provide your staff with the highest quality and most affordable opportunity to learn with a comprehensive package that includes unlimited hours of Education. LOOK FOR THE OPTICON LOGO $ in the daily course grid schedule signifying sessions being developed by Opticon.
## CLINICAL

### CONTACT LENS

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:45AM - 8:15AM</td>
<td>C2C1</td>
<td>A Roadmap for Making the Diagnosis in Glaucoma</td>
<td>Chaglasian, Schmidt</td>
</tr>
<tr>
<td>8:30AM - 9:15AM</td>
<td>C2C2</td>
<td>The OD Role in Diabetes</td>
<td>Reynolds</td>
</tr>
<tr>
<td>9:45AM - 10:45AM</td>
<td>C2C3</td>
<td>Life-Threatening Causes of Diptopia</td>
<td>Melve, Galanis</td>
</tr>
</tbody>
</table>

### OPTICAL TECHNOLOGY

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:15am - 9:15am</td>
<td>C26O1</td>
<td>Soft Lens Fitting - Spherical and Toric</td>
<td>Myopia</td>
</tr>
<tr>
<td>9:45am - 11:45am</td>
<td>C26O2</td>
<td>Management of Profuse Lens Diperception</td>
<td>Myopia</td>
</tr>
<tr>
<td>11:15am - 1:15pm</td>
<td>C26O3</td>
<td>Soft Lens Troubleshooting - Scleral Lens</td>
<td>Novartis</td>
</tr>
<tr>
<td>12:15pm - 2:15pm</td>
<td>C26O4</td>
<td>Soft Lens Fitting - Spherical and Toric</td>
<td>Myopia</td>
</tr>
</tbody>
</table>

### BUSINESS SOLUTIONS

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:15pm - 4:15pm</td>
<td>C26O4</td>
<td>Soft Lens Fitting - Spherical and Toric</td>
<td>Myopia</td>
</tr>
<tr>
<td>4:45pm - 6:45pm</td>
<td>C26O5</td>
<td>Soft Lens Fitting - Spherical and Toric</td>
<td>Myopia</td>
</tr>
</tbody>
</table>

### TRACK KEY

- Anterior Segment
- Glaucoma
- Imaging Technology
- Myopia
- Non-Track
- Optometric/Surgical Procedures
- Ophthalmology
- Pharmacology
- Prosthetic Segments/Reflae
- Scleral Lens
- Surgical/Co-Management
- Systemic Disease/Diabetes

ACCREDITATION IS PENDING

The “pending CE approval” courses are being submitted for accreditation. If the accreditation determination is NOT listed, the course is NOT being submitted to that agency.
SATURDAY
APRIL 2

CLINICAL

8:30AM – 9:30AM
The Secondary Glaucoma Mortality: Is now a focus from 9:45am – 10:45am
Uwels, M. Schaeffer, Schmidt

9:45AM – 10:45AM
Optic Nerve Damage in Glaucoma Considerations May 2021
Fingeret, Schmidt

10:45AM – 11:15AM
20/20 Refractive Surgery Center in the Modern Refractive Setting: How to See Your Refractive Surgery Patients in 2021
Bazemore, Tucker, S. Schaeffer

11:15AM – 12:15PM
10 Hacks for Ophthalmic Surgeons: Saving Lives in the Operating Room
Zeitlin

12:15PM – 1:15PM
Optional Meetings with Neurologists: The Link Between Neurology and Ophthalmology
Hanlin, D. Mann

2:00PM – 3:00PM
Optic Nerve Damage in Glaucoma Considerations May 2021
Fingeret, Schmidt

3:00PM – 4:00PM
Innovative Glaucoma Sciences: Fitting Beyond the Limbus
Roberts

4:00PM – 5:00PM
Cataract Surgery: An Update on the Latest Technologies and Techniques
Zeitlin

CONTACT LENS

8:30AM – 9:30AM
Tricks of the Trade with Torics
Pal

9:30AM – 10:00AM
FDA Clearance for Contact Lens Technologies
Thimons

10:00AM – 11:00AM
OCT Concepts: Maximizing Your OCT Buxton
This course is 2 hours from 10:45am – 12:00pm

11:00AM – 12:00PM
OCT Workshop: What’s New in OCT Interpretation in Glaucoma
Morgan

12:00PM – 1:00PM
OCT Workshop: What’s New in OCT Interpretation in Glaucoma
Morgan

1:00PM – 2:00PM
OCT Workshop: What’s New in OCT Interpretation in Glaucoma
Morgan

2:00PM – 3:00PM
OCT Workshop: What’s New in OCT Interpretation in Glaucoma
Morgan

3:00PM – 4:00PM
OCT Workshop: What’s New in OCT Interpretation in Glaucoma
Morgan

4:00PM – 5:00PM
OCT Workshop: What’s New in OCT Interpretation in Glaucoma
Morgan

5:00PM – 6:00PM
OCT Workshop: What’s New in OCT Interpretation in Glaucoma
Morgan

6:00PM – 7:00PM
OCT Workshop: What’s New in OCT Interpretation in Glaucoma
Morgan

7:00PM – 8:00PM
OCT Workshop: What’s New in OCT Interpretation in Glaucoma
Morgan

8:00PM – 9:00PM
OCT Workshop: What’s New in OCT Interpretation in Glaucoma
Morgan

9:00PM – 10:00PM
OCT Workshop: What’s New in OCT Interpretation in Glaucoma
Morgan

10:00PM – 11:00PM
OCT Workshop: What’s New in OCT Interpretation in Glaucoma
Morgan

ABOUT ACCREDITATION
The accreditation designations serve as a guide to assist you with course selections. The course listed may be low at time of the conference. Please refer to VEE2022.com/Policies for current CE approvals.

Program Subject to Change as of 01/18/22.
## CLINICAL

<table>
<thead>
<tr>
<th>Time</th>
<th>Course Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:15AM - 8:15AM</td>
<td>Clinical Ocular Grand Rounds, Lonsberry (This course is 2 hours from 7:30am - 9:15am)</td>
</tr>
<tr>
<td>8:30AM - 9:30AM</td>
<td>Contact Lens Management of Keratoconus, Johnston (This course is 2 hours from 8:30am - 10:30am)</td>
</tr>
<tr>
<td>9:45AM - 10:45AM</td>
<td>Florida Jurisprudence, Lonsberry (This course is 2 hours from 9:45am - 11:45am)</td>
</tr>
<tr>
<td>11:00AM - 12:00PM</td>
<td>Urgency vs. Emergency, Koetting (This course is 2 hours from 10:00am - 12:00pm)</td>
</tr>
<tr>
<td>12:15PM - 1:15PM</td>
<td>Florida Prevention of Medical Errors, Sowka (This course is 2 hours from 12:15pm - 2:15pm)</td>
</tr>
</tbody>
</table>

## Scleral Lens

### Non-Track

<table>
<thead>
<tr>
<th>Time</th>
<th>Course Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:15AM - 9:15AM</td>
<td>Scleral Lens, Non-Track (This course is 2 hours from 7:15am - 9:15am)</td>
</tr>
</tbody>
</table>

## CONTACT LENS

<table>
<thead>
<tr>
<th>Time</th>
<th>Course Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:15AM - 9:15AM</td>
<td>Contact Lens Management of Infants and Children, Johnston (This course is 2 hours from 8:15am - 10:15am)</td>
</tr>
</tbody>
</table>

## OPTICAL TECHNOLOGY

### 41C2

<table>
<thead>
<tr>
<th>Time</th>
<th>Course Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:15AM - 9:15AM</td>
<td>C31: Anterior Segment Case Files, Whitley, Koetting (This course is 2 hours from 7:30am - 9:30am)</td>
</tr>
</tbody>
</table>

### 42C1

<table>
<thead>
<tr>
<th>Time</th>
<th>Course Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:15AM - 9:15AM</td>
<td>Red Eyes – It’s Just Conjunctivitis or Is It?, Johnston</td>
</tr>
</tbody>
</table>

### 43C3

<table>
<thead>
<tr>
<th>Time</th>
<th>Course Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:15AM - 9:15AM</td>
<td>Treatment and Management of Glaucoma, Lonsberry (This course is 2 hours from 7:15am - 9:15am)</td>
</tr>
</tbody>
</table>

## BUSINESS SOLUTIONS

### 41B1

<table>
<thead>
<tr>
<th>Time</th>
<th>Course Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:15AM - 9:15AM</td>
<td>The Lean Machine: A Systematic Approach to an Efficient and Cost Effective Practice, Neufeld</td>
</tr>
</tbody>
</table>

### 41B2

<table>
<thead>
<tr>
<th>Time</th>
<th>Course Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:15AM - 9:15AM</td>
<td>The Lost Art: GP Contact Lens Fitting, Quinn, Bennett</td>
</tr>
</tbody>
</table>

## TRACK KEY

- **Anterior Segment**
- **Glaucoma**
- **Imaging Technology**
- **Myopia**
- **Non-Track**
- **Ophthalmic/Surgical Procedures**
- **Pharmacology**
- **Posterior Segment/Retina**
- **Scleral Lens**
- **Surgical/Co-Management**
- **Systemic Disease/Diabetes**
Meet your newest irreplaceable team member!

Fully automated wavefront lens analyzer

The VX40 is fully automated and gives you everything you need with the push of a button in 30 seconds. Featured on Review of Optometric Business, the article “How to Sell Near-Task-Specific Glasses & Generate $160,000+ Annually” explores the opportunity to expand profitability by selling Near-Task-Specific Lenses. The VX40 reads all lenses, including bifocals, progressives, freeform, and single vision lenses. It is compatible with virtually every lens technology and brand.

Visit us at booth #F4133 to experience a live demo of the VX40 and the rest of our integrated portfolio!

We are the global manufacturer and exclusive sales, service and training provider for Optovue, Visionix, Briot and Weco brands in North America. You can read about these emerging technologies, and more on our Digital Catalog. Scan QR code.

Luneau Technology

Prism is
Niche

Unnecessary
Not Worth It

Problematic
Complicated

Difficult
Avoidable

A Speciality
Poison

The Future

Brought to you by
REGENERON

PUT YOUR PATIENTS WITH DIABETIC RETINOPATHY (DR) ON THE PATH TOWARD MANAGING THEIR DISEASE AND

SET THE COURSE FOR SUCCESS IN DR

DIABETIC RETINOPATHY: A GROWING PROBLEM THAT YOU CAN HELP MANAGE

Through early detection, monitoring, and timely referral, you play a pivotal role in managing your DR patients’ vision.

If you see or suspect DR:

- Educate your patients about the severity of DR, especially when left untreated:
  - Your early and frequent discussions about disease progression, treatment options, and referral will empower patients, which could help them avoid significant vision loss.

- According to the AOA, you should refer patients with:
  - Severe nonproliferative DR (NPDR) within 2 to 4 weeks
  - Proliferative DR (PDR) within 2 to 4 weeks
  - High-risk PDR with or without macular edema within 24 to 48 hours

- Ensure patients have followed up with a retina specialist who can treat DR

- Monitor your patients with DR:
  - The AOA recommends frequent monitoring of patients:
    - At least every 6 to 8 months in patients with moderate NPDR and more frequently for patients with greater disease severity

- Refer patients to a specialist who can treat DR:

Regeneron is committed to helping you partner with your patients for comprehensive care of DR, as well as for care of other retinal diseases.

AOA = American Optometric Association


© 2016, Regeneron Pharmaceuticals, Inc. All rights reserved.

727 Old Saw Mill River Road, Tarrytown, NY 10591

1 (800) 729-1959

luneautechusa.com/visionexpo

12/6/2021 8:11:05 PM

OPH-20-01-0007_REEYR21308_OD Unbranded Ad_VEE_2022_Outlined_FINAL.indd 1

12/1/21 5:00 PM
Experience a complete suite of advanced visual health solutions

We are the global manufacturer and exclusive sales, service, and training provider for Optovue®, Visenix®, Brain and Wec® brands in North America.

We are the pioneers in integrating core refractive, screening, and imaging technologies to address the needs of eye care professionals in this dynamic market. Today, we are proud to offer high-speed OCT and OCTA technology designed to facilitate diagnosing and managing a range of ocular diseases.

Our goal is to improve access to forward-thinking technology that transforms the patient experience. With over 100 years of innovation, an expanded product line, as well as a new level of support, clinical education, and practice integration, we are well positioned to help you unlock your potential.

The latest in OCT and OCTA

Avanti Widefield OCT offers state-of-the-art imaging from the cornea to the choroid with exclusive technology that will change your approach to diagnosis and management. When you’re ready, add Visenix OCT Angiography (CTA) to the Avanti platform to bring non-invasive vascular imaging with measurement tools to your practice. Ease into OCTA with AngioVue Essential or choose AngioVue Comprehensive to access all available OCTA features. For the retina specialist, there’s AngioVue Retina, retinal-only OCT and OCTA.

New technologies to thrive in the next normal

The Visions product line combines multiple test functionalities in a small package—providing all necessary data for a comprehensive exam with significantly less patient movement from instrument to instrument. The compact Eye Refract and VX650 can be placed on a single tabletop or set up separately in a five square feet pre-test room. The optional table’s ergonomic design even allows a wheelchair to fit comfortably, an excellent benefit for practitioners who see patients with special needs.

The second-generation Eye Refract is a highly automated and dynamic wavefront-based phoropter that includes a digital axially short chart and the VX40 lens analyzer. The new VX650 combines a 45-degree fundus camera with advanced objective refraction, topography, wavefront aberrometry, tomography, and more.

New product releases to be revealed at booth #F4133! Experience it yourself at Vision Expo East.

You can read about these emerging technologies, and more on our Digital Catalog, Scan QR code.

CHOOSE XIIDRA,

For additional safety information about Xiidra®, please refer to the brief summary of Prescribing Information below.

Xiidra® (lifitegrast ophthalmic solution), for topical ophthalmic use Initial U.S. Approval: 2016

BRIEF SUMMARY: Please see package insert for full prescribing information.

1 INDICATIONS AND USAGE

Xiidra® (lifitegrast ophthalmic solution) 0.05% is indicated for the treatment of the signs and symptoms of dry eye disease (DED).

2 CONTRAINDICATIONS

Xiidra® is contraindicated in patients with known hypersensitivity to lifitegrast or any of the other ingredients in the formulation (see Adverse Reactions (6.2)).

6 ADVERSE REACTIONS

The following serious adverse reactions are described elsewhere in the labeling:

• Hypersensitivity (see Contraindications (4))

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In five clinical studies of DED conducted with lifitegrast ophthalmic solution, 1401 patients received at least one dose of lifitegrast (1287 of which received lifitegrast 0.05%). The majority of patients (84%) had a 3 months of treatment exposure. One hundred-seventy patients were exposed to lifitegrast for approximately 12 months. The majority of the treated patients were female (77%). The most common adverse reactions reported in 5%-25% of patients were instillation-site irritation, dysgeusia, and reduced visual acuity. Other adverse reactions reported in 1%-5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus, and asthenopia.

6.2 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of Xiidra. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Rare cases of hypersensitivity, including anaphylactic reaction, bronchospasm, respiratory distress, dyspnea, asthma, urticaria, angioedema, and anaphylaxis have been reported. Eye swelling and rash have been reported (see Contraindications (4)).

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

There are no available data on Xiidra use in pregnant women to inform any drug-associated risks. Intravenous (IV) administration of lifitegrast to pregnant rats, from pre-mating through gestation Day 17, did not produce teratogenicity at clinically relevant systemic exposures. Intravenous administration of lifitegrast to pregnant rabbits during organogenesis produced an increased incidence of omphalocele at the lowest dose tested. 3 mg/kg/day (400-fold the human plasma exposure at the recommended human ophthalmic dose (RHOD), based on the area under the curve [AUC]) neonates. Since human systemic exposure to lifitegrast following ocular administration of Xiidra to the RHOD is low, the applicability of animal findings to the risk of Xiidra use in humans during pregnancy is unclear (see Clinical Pharmacology (12.2)) in the full prescribing information).

Data

Animal Data

Lifitegrast administered daily by IV injection to rats, from pre-mating through gestation Day 17, caused an increase in mean pre-implantation loss and an increased incidence of several minor skeletal anomalies at 30 mg/kg/day (200-fold higher plasma exposure at the RHOD, based on AUC). In the rabbit, an increased incidence of omphalocele was observed at the lowest dose tested. 3 mg/kg/day (400-fold human plasma exposure at the RHOD, based on AUC). In the rabbit, an increased incidence of omphalocele was observed at the lowest dose tested. 3 mg/kg/day (400-fold human plasma exposure at the RHOD, based on AUC) when administered by IV injection from gestation Days 7 through 19. A fetal no observed adverse effect level (NOAEL) was not identified in the rabbit.

8.2 Lactation

Risk Summary

There are no data on the presence of lifitegrast in human milk, the effects on the breastfed infant, or the effects on milk production. However, systemic exposure to lifitegrast from ocular administration is low (see Clinical Pharmacology (12.2)) in the full prescribing information). The developmental and health benefits of breastfeeding should be considered, along with the mother’s clinical need for Xiidra and any potential adverse effects on the breastfed child from Xiidra.

8.4 Pediatric Use

Safety and efficacy in pediatric patients below the age of 17 years have not been established.

8.5 Geriatric Use

No overall differences in safety or effectiveness have been observed between elderly and younger adult patients.

Manufactured by: Novartis Pharmaceuticals Corporation
One Health Plaza
East Hanover, NJ 07936
T2019-110

Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080

© 2021 Novartis

For additional information, visit www.xiidra.com or call 1 (800) 729-1959

For additional information, visit www.xiidra.com or call 1 (800) 729-1959

CHOOSE XIIDRA,

VISIT BOOTH #F4255 TO LEARN MORE

In dry eye disease, don’t let chronic inflammation overwhelm.

For additional safety information about Xiidra®, please refer to the brief summary of Prescribing Information below.

* Xiidra blocks LFA-1 on T cells binding with ICAM-1 that may be overexpressed on the ocular surface in dry eye disease and may prevent formation of an immunologic synapse which, based on in vitro studies, may inhibit T-cell activation, migration of activated T cells to the ocular surface, and reduce cytokine release. The exact mechanism of action of Xiidra in DED is not known. 1


XIIDRA, the XIIDRA logo and i are registered trademarks of Novartis AG.

Unveiled control of less quality

Brie Couture is a highly intuitive finishing solution for any Optical. Inspired by our popular Brie Optometry finishes, Couture is the world’s first finishing platform that is powered by innovative virtual 3D rendering technology, allowing Opticians to visualize the final output before editing.

Live demo at booth #F4133

Unveiled control of less quality

Brie Couture is a highly intuitive finishing solution for any Optical. Inspired by our popular Brie Optometry finishes, Couture is the world’s first finishing platform that is powered by innovative virtual 3D rendering technology, allowing Opticians to visualize the final output before editing.

Live demo at booth #F4133

1-800-729-1959

luneautechusa.com/visionexpo

VISIT BOOTH #F4255 TO LEARN MORE

In dry eye disease, don’t let chronic inflammation overwhelm.

CHOOSE XIIDRA,

VISIT BOOTH #F4255 TO LEARN MORE

In dry eye disease, don’t let chronic inflammation overwhelm.

CHOOSE XIIDRA,

VISIT BOOTH #F4255 TO LEARN MORE
iCare EIDON

Eidon Ultra-Widefield:
Now covering 200 degrees

iCare’s unique combination of sharpness and TrueColor offers now even wider view on the retina from 120 with a single shot, up to 200 with Mosaic functionality, helping to detect subtle signs of pathologies further in the periphery.*

+ Ultra-Widefield of view up to 200°
+ Rich in details from center to periphery
+ Imaging through media opacities

* Ultra-Widefield imaging is available with the optional EIDON UWF Module.

iCare IC200
200 degrees of tonometry

+ Supine, recline & seated operations
+ No corneal disruptions
+ Suitable for every patient
+ Single use probes to exceed infection control guidelines

For more information, scan, call 888.422.7313, or email infoUSA@icare-world.com
www.icare-world.com/USA

For better perception

REGISTRATION IS NOW OFFICIALLY OPEN!

VEE2022.com/Register